IL300115A - Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA) - Google Patents
Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)Info
- Publication number
- IL300115A IL300115A IL300115A IL30011523A IL300115A IL 300115 A IL300115 A IL 300115A IL 300115 A IL300115 A IL 300115A IL 30011523 A IL30011523 A IL 30011523A IL 300115 A IL300115 A IL 300115A
- Authority
- IL
- Israel
- Prior art keywords
- hsct
- tma
- antibodies
- dosage
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065107P | 2020-08-13 | 2020-08-13 | |
| PCT/US2021/045823 WO2022036151A1 (en) | 2020-08-13 | 2021-08-12 | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300115A true IL300115A (en) | 2023-03-01 |
Family
ID=77655658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300115A IL300115A (en) | 2020-08-13 | 2021-08-12 | Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209071A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4196161A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7821160B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230047179A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249550A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021326526B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173007A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300115A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001702A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022036151A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性(hsct-tma)的抗c5抗體的補充劑量和投與 |
| CA3266977A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| ES2796078T3 (es) * | 2013-09-16 | 2020-11-25 | Childrens Hospital Med Ct | Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CA3024618A1 (en) * | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与 |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US20230416344A1 (en) * | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
-
2021
- 2021-08-12 JP JP2023509698A patent/JP7821160B2/ja active Active
- 2021-08-12 US US18/018,936 patent/US20240209071A1/en active Pending
- 2021-08-12 MX MX2023001702A patent/MX2023001702A/es unknown
- 2021-08-12 IL IL300115A patent/IL300115A/en unknown
- 2021-08-12 WO PCT/US2021/045823 patent/WO2022036151A1/en not_active Ceased
- 2021-08-12 AU AU2021326526A patent/AU2021326526B2/en active Active
- 2021-08-12 CA CA3173007A patent/CA3173007A1/en active Pending
- 2021-08-12 CN CN202180050198.2A patent/CN116249550A/zh active Pending
- 2021-08-12 EP EP21766299.8A patent/EP4196161A1/en active Pending
- 2021-08-12 KR KR1020237008325A patent/KR20230047179A/ko active Pending
-
2025
- 2025-11-26 JP JP2025204019A patent/JP2026026191A/ja active Pending
-
2026
- 2026-03-11 AU AU2026201836A patent/AU2026201836A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7821160B2 (ja) | 2026-02-26 |
| CA3173007A1 (en) | 2022-02-17 |
| CN116249550A (zh) | 2023-06-09 |
| EP4196161A1 (en) | 2023-06-21 |
| JP2023539047A (ja) | 2023-09-13 |
| KR20230047179A (ko) | 2023-04-06 |
| AU2021326526A1 (en) | 2023-03-02 |
| WO2022036151A1 (en) | 2022-02-17 |
| MX2023001702A (es) | 2023-03-09 |
| JP2026026191A (ja) | 2026-02-16 |
| US20240209071A1 (en) | 2024-06-27 |
| AU2026201836A1 (en) | 2026-05-21 |
| AU2021326526B2 (en) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277025A (en) | Methods for improving the differentiation of stem cells into beta cells | |
| IL289011A (en) | Use of chimeric antigen receptor t cells and nk cell inhibitors to treat cancer | |
| EA202190162A2 (ru) | Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13 | |
| CR20210088A (es) | Composiciones de anticuerpos fcrn y métodos de uso de estos | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| SG10201807042YA (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| MX2019000704A (es) | Celulas madre mesenquimales primarias inmunoprotectoras y metodos. | |
| SI4121007T1 (sl) | Formulacije protiteles proti amiloidnemu beta peptidnemu protofibrilu z visoko koncentracijo in načini njihove uporabe | |
| IL316368A (en) | Anti-TL1A antibodies and methods of using them | |
| SG11202010150PA (en) | Monoclonal antibody of nerve growth factor and encoding gene and use thereof | |
| IL319413A (en) | Adjunctive dosing and administration of anti-C5 antibodies for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). | |
| IL319674A (en) | Human anti-IL-1R3 antibody and methods of use | |
| HK40088954A (en) | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) | |
| PL4031569T3 (pl) | Przeciwciała przeciwko czynnikowi wzrostu komórek macierzystych i sposoby ich zastosowania | |
| IL288496A (en) | A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-il23 antibody | |
| IL315845A (en) | Anti-dectin-1 antibodies and methods of using them | |
| IL314656A (en) | A component for a transfer system and a method and device for producing a component for a transfer system | |
| Studentsov et al. | Adaptogens and related groups of drugs-50 years of searching | |
| MX2023001702A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). | |
| IL242791B (en) | Antibodies against the toxin ricin | |
| IL319208A (en) | Treating asthma with anti-interleukin-33 antibody | |
| IL325425A (en) | Dosage and treatment of vaccine-mediated diseases Biomarkers associated with vaccine-mediated diseases | |
| IL318694A (en) | Antibodies against CCR8 and methods of using them | |
| BR112022025020A2 (pt) | Dosagem de anticorpos neutralizantes de poliomavírus | |
| IL317690A (en) | Anti-GPNMB antibodies and methods of using them |